Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051120 | 0.86 | FOLH1 (0.65) | FOLH1PTGESALOX5PPARGSRD5A2 | |
| SCHEMBL5054646 | 0.85 | FOLH1 (0.69) | FOLH1PTGESALOX5PPARGCPA3 | |
| SCHEMBL5057981 | 0.84 | FOLH1 (0.61) | FOLH1PTGESALOX5PPARG | |
| SCHEMBL5051236 | 0.83 | FOLH1 (0.74) | FOLH1 | |
| SCHEMBL5053331 | 0.81 | FOLH1 (0.68) | FOLH1CPA3 | |
| SCHEMBL5054570 | 0.80 | FOLH1 (0.46) | FOLH1PTGESALOX5PPARG | |
| SCHEMBL5054573 | 0.79 | FOLH1 (0.50) | FOLH1PPARGAKR1C3 | |
| SCHEMBL2058464 | 0.78 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL5053104 | 0.77 | FOLH1 (0.65) | FOLH1 | |
| SCHEMBL5053346 | 0.76 | FOLH1 (0.60) | FOLH1PTGESALOX5PPARGCPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-6586623-B2 | Carbocyclic mercaptans such as 3-carboxy-alpha-(3-mercapto-propyl) benzenepropanoic acid, used as N-acetylated alpha-linked acidic dipeptidase(NAALADase) inhibitors and for medical diadnosis | GUILFORD PHARMACEUTICALS INC. | 2003-07-01 | — | — | US | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885PTGES 298/4885ALOX5 1686/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885PTGES 4094/4885ALOX5 4088/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885PTGES 298/4885ALOX5 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.